Literature DB >> 21881594

Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis.

S A Greenberg1, B W Higgs, C Morehouse, R J Walsh, S Won Kong, P Brohawn, W Zhu, A Amato, M Salajegheh, B White, P A Kiener, B Jallal, Y Yao.   

Abstract

The objective of this study was to evaluate the relationship between blood mRNA, disease activity and treatment effects in a longitudinal study of patients with dermatomyositis (DM) or polymyositis (PM). In all, 24 patients with DM or PM were followed for up to 6 years (mean of 1.9 years) at 2-7 follow-up visits while receiving standard clinical care. Clinical data and blood samples collected at 80 patient visits were used for the analysis of cytokine-induced gene expression for the signaling pathways of type 1 interferon (IFN), tumor necrosis factor-α, IL-1β, granulocyte-monocyte colony-stimulating factor, IL-10 and IL-13. A type 1 IFN signature score, but not other cytokine signature scores in the blood of patients with DM or PM, correlated highly with disease activity, decreased significantly with immunomodulatory therapies and showed concordant changes with major changes in disease activity. Type 1 IFN signature score in the blood correlates with disease activity in longitudinal follow-up of individual patients with DM or PM. The type 1 IFN-inducible gene transcripts in the blood have potential utility for monitoring disease activity in patients with DM or PM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881594     DOI: 10.1038/gene.2011.61

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  49 in total

Review 1.  Type I interferon in the pathogenesis of lupus.

Authors:  Mary K Crow
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

2.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

Review 3.  The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.

Authors:  S Ahmed; K L Chen; V P Werth
Journal:  Semin Arthritis Rheum       Date:  2020-01-11       Impact factor: 5.532

Review 4.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 5.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

6.  Identification of novel autoantigens by a triangulation approach.

Authors:  Tricia R Cottrell; John C Hall; Antony Rosen; Livia Casciola-Rosen
Journal:  J Immunol Methods       Date:  2012-08-11       Impact factor: 2.303

Review 7.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 8.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 9.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623

Review 10.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.